Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in the region has become impossible to ignore.  | Amid the U.S.' war with Iran, ...

Although the window for Rhythm Pharmaceuticals’ Imcivree to break out of the genetic obesity realm is quickly approaching with an upcoming FDA decision, a few other potential areas of expansio | The ...

Indiana is looking to build on the swell of investments that have poured in fr | Indiana's governor Mike Braun aims to create ...

Maggie Hassan. The setup forced many users to pay higher prices and allowed the British drugmaker to avoid paying Medicaid ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines ...

In its fifth year, the annual Hologic Global Women’s Health Index found only minimal improvements in preventive screening ...

BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—currently approved in achondroplasia, a ...

Johnson & Johnson is suing a former oncology medical affairs employee, alleging a massive and “malicious” stealing of trade ...

It was only nine months ago that Idorsia announced a CEO change, tapping Srishti Gupt | Idorsia is gearing up for another CEO ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...

With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...